HGH Fragment 176-191: Evidence, Mechanism & Legal Status

HGH Fragment 176-191 (often given in the laboratory as the 177-191 peptide) is the carboxy-terminal region of human growth hormone, sold by peptide vendors as a fat-loss compound. Its popularity in physique and weight-loss circles is large; its proof in humans is essentially absent. This monograph separates the genuine, modest animal biology from the marketing.1

This article is informational and editorial content for research and educational purposes only. It is not medical advice, not a protocol to follow, and not a sourcing guide. HGH Fragment 176-191 is not an FDA-approved drug; it is sold as a "research chemical not for human use" and is prohibited in sport. Dosing figures are reported strictly as seen in the published literature for completeness — not as recommendations. Consult a licensed clinician before any health decision.

What is HGH Fragment 176-191 and how does it work?

Human growth hormone is a 191-amino-acid protein whose growth-promoting (somatogenic/IGF-1) activity and metabolic (lipid) activity map to different regions of the molecule — a structure-function separation recognized since the 1970s.2 The lipid-active domain sits at the C-terminus. In the foundational synthetic-peptide work the active sequence is given as hGH 177-191 (Leu-Arg-Ile-Val-Gln-Cys-Arg-Val-Ser-Glu-Gly-Ser-Cys-Gly-Phe); the commercially sold "176-191" peptide is the same region, with numbering conventions differing by one residue.1 It contains two cysteines that form an intramolecular disulfide loop, and reducing that bond markedly diminishes activity, indicating the loop is structurally required.4

The mechanism — all of it preclinical — does not involve the classical GH receptor. The fragment and its analogue do not compete with hGH for GHR binding and do not raise IGF-1.5 The leading hypothesis is β3-adrenergic-receptor (β3-AR) dependent. In the pivotal mechanistic study, both intact hGH and AOD-9604 restored the suppressed β3-AR messenger RNA of obese mice toward lean-control levels, and the metabolic effects (increased energy expenditure, fat oxidation, decreased body-weight gain) were abolished in β3-AR knockout mice — the receptor is required for the response.5 At the enzyme level, the C-terminal domain stimulated hormone-sensitive lipase and inhibited acetyl-CoA carboxylase (a lipogenic enzyme) in isolated rat adipose tissue.4 No validated half-life is published for the unmodified fragment; small unmodified peptides of this size are expected to be cleared within minutes, which is part of why the stabilized AOD-9604 was developed.6

What is the evidence by indication?

There are no human RCTs of HGH Fragment 176-191 itself for any use; the table below grades the fragment's evidence honestly, and separates it from the analogue's human data.

What the animal work actually showed for the fragment: in isolated rat adipose tissue the synthetic C-terminal sequence reproduced hGH's antilipogenic action but showed no significant lipolytic effect (no increase in glycerol release).1 Chronic treatment of obese (ob/ob) mice with hGH 177-191 reduced cumulative body-weight gain and adipose-tissue mass and significantly inhibited lipogenesis.3 The domain (as AOD9401/AOD9604) reduced adipocyte diameter in obese Zucker rats without inducing insulin resistance or glucose intolerance.4 The fairest reading is that the dominant, most reproducible action of this domain is inhibition of making new fat, with lipolytic/β3-mediated effects shown chiefly for the stabilized analogue in animals.5

What the human trials of AOD-9604 (the analogue) showed: across six randomized, double-blind, placebo-controlled trials in roughly 893 participants the compound was very safe, but the program did not deliver clinically meaningful weight loss.6 An earlier ~12-week study reported a modest signal (about 2.6 kg loss versus 0.8 kg placebo at the favorable dose), but the pivotal 24-week Phase 2b trial in 502 obese adults failed its primary weight-loss endpoint versus placebo, and obesity development was discontinued in 2007. The negative pivotal result was never published as a standalone peer-reviewed efficacy paper — itself a red flag. For the unmodified fragment, human efficacy is unproven (Grade C); for the analogue with the best human data, efficacy is essentially null. The 2026 WADA Prohibited List is published at wada-ama.org for readers who want the primary anti-doping text.11

What doses appear in the literature?

Reported strictly as information, not a protocol. No controlled human trial validated any dose or route of the unmodified fragment, so there is no manufacturer prescribing information, no validated concentration, and no quality assurance on research-grade material.6 The published human program studied the analogue AOD-9604 by intravenous (25-400 µg/kg single doses) and oral routes (0.25 mg up to 54 mg); notably, subcutaneous injection was not among the routes in that published human program.6 By contrast, real-world anecdotal "HGH Frag" use is almost universally subcutaneous, with online and clinical-use write-ups commonly describing about 250-500 mcg per dose, sometimes split into a morning and pre/post-exercise dose on an empty stomach — these figures are conventional lore, not trial-derived, and are reported here only for completeness.6 Oral bioavailability of the AOD-9604 hexadecapeptide was low in human studies, and the higher oral doses drove most of the GI adverse events.6

How safe is HGH Fragment 176-191?

Human adverse-event data come from the AOD-9604 program — the only sizeable human dataset, and a different molecule. AOD-9604 showed a safety and tolerability profile indistinguishable from placebo, with no treatment-related serious adverse events across all six trials.6 In IV studies headache was the dominant complaint (mild-to-moderate in up to about 70% in one obese-male study), with transient mild euphoria in a minority. Oral studies showed dose-related GI effects — diarrhea, flatulence, nausea, increased appetite — most prominent at 54 mg. Reassuringly there was no IGF-1 elevation, no glucose intolerance, no insulin resistance, and no anti-drug antibodies detected up to 24 weeks — mechanistically expected because the fragment cannot dimerize the GH receptor.6

The dominant theoretical concern is the GH-axis-adjacent tumor/proliferation caution in anyone with active or prior malignancy; the reassuring counterpoint is that the fragment and AOD-9604 do not raise IGF-1 and do not bind the GH receptor, which removes the principal IGF-1-mediated proliferative pathway — though long-term human oncologic data are absent.5 In practice the largest real-world hazard is product quality: unapproved "research" peptides carry risks of mislabeling, under- or over-dosing, endotoxin or microbial contamination, and unverified identity — none captured by the clean clinical-trial record of pharmaceutical-grade AOD-9604.7 Pregnancy, breastfeeding, and pediatric use are precautionary contraindications because no data exist.

What is the FDA and WADA status in 2026?

Neither HGH Fragment 176-191 nor AOD-9604 is FDA-approved for any indication; there is no NDA or BLA, and the molecule never cleared Phase 3 (obesity development ended in 2007).6 On compounding, AOD-9604 (free base and acetate) was nominated for the 503A bulks list for weight loss, osteoporosis and osteoarthritis; the original nominations were withdrawn, and the FDA continued evaluation on its own initiative, noting there is no USP monograph for the substance.7 The FDA's Pharmacy Compounding Advisory Committee evaluated AOD-9604 at its December 2024 meeting, and the agency's analysis weighed the bulks-list criteria against inclusion, with the substance not placed on the 503A bulks list.89 Under the finalized interim policy (January 7, 2025) the FDA also stated it does not intend to add newly nominated substances to the interim framework.10 The practical effect: AOD-9604/hGH-fragment compounding has no clear lawful path under 503A, and the unmodified fragment likewise lacks any approved or sanctioned status — it is sold only as a "research chemical, not for human use."

For athletes the picture is unambiguous. The compound is prohibited at all times — in and out of competition — under Section S2.2.3 (growth hormone, its fragments and analogues), and the WADA Prohibited List names "growth hormone fragments, e.g. AOD-9604 and hGH 176-191" as explicit examples.11 No automatic Therapeutic Use Exemption applies, and athletes face sanction for use.12 It is not a DEA-controlled substance, but non-scheduling does not make non-research human use lawful.

Bottom line. HGH Fragment 176-191 has a genuine but modest metabolic biology — in animals and isolated fat cells the C-terminal domain inhibits lipogenesis and (as the stabilized analogue AOD-9604) activates hormone-sensitive lipase through a β3-adrenergic pathway, without raising IGF-1. But its billing as a "proven fat-loss peptide" is not supported by human evidence: there are zero human RCTs of the fragment, the strongest human data belong to a different molecule that failed its pivotal weight-loss trial, there is no validated dose or route, and it is banned in sport. The proven mechanism is interesting; the human clinical promise is, at best, unrealized and, at worst, contradicted by the best available trial. Regulatory facts here are current as of June 2026 and should be re-verified for later anti-doping and compounding updates.